The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
Diffuse Large B Cell Lymphoma (DLBCL)
DRUG: Glofitamab|DRUG: Obinutuzumab
Progression free survival (PFS) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, Baseline up to end of study (EOS) (approximately 48 months)
Complete Response Rate (CRR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, Baseline up to EOS (approximately 48 months)|Overall Response Rate (ORR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, Baseline up to EOS (approximately 48 months)|Duration of Response (DoR), From the date of the first occurrence of a documented CR or partial response (PR) to the date of progression, relapse, or death from any cause, whichever occurs first (up to approximately 48 months)|Duration of Complete Response (DoCR), From the date of the first occurrence of a documented CR to the date of progression, relapse, or death from any cause, whichever occurs first (up to approximately 48 months)|Time to Next Treatment (TTNT), From the start of glofitamab treatment to the initiation of next-line treatment (up to approximately 48 months)|Overall Survival (OS), From the start of glofitamab treatment until the date of death from any cause (up to approximately 48 months)
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.